FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100661360> ?p ?o ?g. }

• W2100661360 endingPage "2754" @default.
• W2100661360 startingPage "2745" @default.
• W2100661360 abstract "Abstract Purpose: We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab. Experimental Design: This double-blind, randomized, placebo-controlled phase IIb study (ClinicalTrials.gov NCT00493636) enrolled patients with locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)–negative breast cancer and prior bevacizumab treatment. Patients were randomized to chemotherapy with sorafenib (400 mg, twice daily) or matching placebo. Initially, chemotherapy was gemcitabine (1,000 mg/m2 i.v., days 1, 8/21), but later, capecitabine (1,000 mg/m2 orally twice daily, days 1–14/21) was allowed as an alternative. The primary endpoint was progression-free survival (PFS). Results: One hundred and sixty patients were randomized. More patients received gemcitabine (82.5%) than capecitabine (17.5%). Sorafenib plus gemcitabine/capecitabine was associated with a statistically significant prolongation in PFS versus placebo plus gemcitabine/capecitabine [3.4 vs. 2.7 months; HR = 0.65; 95% confidence interval (CI): 0.45–0.95; P = 0.02], time to progression was increased (median, 3.6 vs. 2.7 months; HR = 0.64; 95% CI: 0.44–0.93; P = 0.02), and overall response rate was 19.8% versus 12.7% (P = 0.23). Median survival was 13.4 versus 11.4 months for sorafenib versus placebo (HR = 1.01; 95% CI: 0.71−1.44; P = 0.95). Addition of sorafenib versus placebo increased grade 3/4 hand–foot skin reaction (39% vs. 5%), stomatitis (10% vs. 0%), fatigue (18% vs. 9%), and dose reductions that were more frequent (51.9% vs. 7.8%). Conclusion: The addition of sorafenib to gemcitabine/capecitabine provided a clinically small but statistically significant PFS benefit in HER2-negative advanced breast cancer patients whose disease progressed during/after bevacizumab. Combination treatment was associated with manageable toxicities but frequently required dose reductions. Clin Cancer Res; 19(10); 2745–54. ©2013 AACR." @default.
• W2100661360 created "2016-06-24" @default.
• W2100661360 creator A5000991422 @default.
• W2100661360 creator A5003887338 @default.
• W2100661360 creator A5007714289 @default.
• W2100661360 creator A5019593576 @default.
• W2100661360 creator A5032020875 @default.
• W2100661360 creator A5034923448 @default.
• W2100661360 creator A5040457482 @default.
• W2100661360 creator A5047616575 @default.
• W2100661360 creator A5047713528 @default.
• W2100661360 creator A5047918797 @default.
• W2100661360 creator A5049161137 @default.
• W2100661360 creator A5051351236 @default.
• W2100661360 creator A5052023186 @default.
• W2100661360 creator A5056455853 @default.
• W2100661360 creator A5071176191 @default.
• W2100661360 creator A5071199136 @default.
• W2100661360 creator A5072563567 @default.
• W2100661360 creator A5074489260 @default.
• W2100661360 creator A5076489880 @default.
• W2100661360 creator A5085797478 @default.
• W2100661360 creator A5090188675 @default.
• W2100661360 creator A5090359583 @default.
• W2100661360 date "2013-05-12" @default.
• W2100661360 modified "2023-09-26" @default.
• W2100661360 title "Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab" @default.
• W2100661360 cites W1965874702 @default.
• W2100661360 cites W1967600348 @default.
• W2100661360 cites W1997533142 @default.
• W2100661360 cites W2003999835 @default.
• W2100661360 cites W2009930501 @default.
• W2100661360 cites W2013246214 @default.
• W2100661360 cites W2029197596 @default.
• W2100661360 cites W2044016094 @default.
• W2100661360 cites W2045316633 @default.
• W2100661360 cites W2068014745 @default.
• W2100661360 cites W2068532424 @default.
• W2100661360 cites W2078452680 @default.
• W2100661360 cites W2080557886 @default.
• W2100661360 cites W2085529853 @default.
• W2100661360 cites W2091246698 @default.
• W2100661360 cites W2103563357 @default.
• W2100661360 cites W2104599448 @default.
• W2100661360 cites W2107464516 @default.
• W2100661360 cites W2108998596 @default.
• W2100661360 cites W2115731038 @default.
• W2100661360 cites W2124714703 @default.
• W2100661360 cites W2126275851 @default.
• W2100661360 cites W2127457632 @default.
• W2100661360 cites W2131528383 @default.
• W2100661360 cites W2131705241 @default.
• W2100661360 cites W2139248078 @default.
• W2100661360 cites W2140088548 @default.
• W2100661360 cites W2147094816 @default.
• W2100661360 cites W2153982924 @default.
• W2100661360 cites W2165906785 @default.
• W2100661360 cites W2166788033 @default.
• W2100661360 cites W2167224460 @default.
• W2100661360 cites W2589745244 @default.
• W2100661360 doi "https://doi.org/10.1158/1078-0432.ccr-12-3177" @default.
• W2100661360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23444220" @default.
• W2100661360 hasPublicationYear "2013" @default.
• W2100661360 type Work @default.
• W2100661360 sameAs 2100661360 @default.
• W2100661360 citedByCount "63" @default.
• W2100661360 countsByYear W21006613602013 @default.
• W2100661360 countsByYear W21006613602014 @default.
• W2100661360 countsByYear W21006613602015 @default.
• W2100661360 countsByYear W21006613602016 @default.
• W2100661360 countsByYear W21006613602017 @default.
• W2100661360 countsByYear W21006613602018 @default.
• W2100661360 countsByYear W21006613602019 @default.
• W2100661360 countsByYear W21006613602020 @default.
• W2100661360 countsByYear W21006613602021 @default.
• W2100661360 countsByYear W21006613602022 @default.
• W2100661360 countsByYear W21006613602023 @default.
• W2100661360 crossrefType "journal-article" @default.
• W2100661360 hasAuthorship W2100661360A5000991422 @default.
• W2100661360 hasAuthorship W2100661360A5003887338 @default.
• W2100661360 hasAuthorship W2100661360A5007714289 @default.
• W2100661360 hasAuthorship W2100661360A5019593576 @default.
• W2100661360 hasAuthorship W2100661360A5032020875 @default.
• W2100661360 hasAuthorship W2100661360A5034923448 @default.
• W2100661360 hasAuthorship W2100661360A5040457482 @default.
• W2100661360 hasAuthorship W2100661360A5047616575 @default.
• W2100661360 hasAuthorship W2100661360A5047713528 @default.
• W2100661360 hasAuthorship W2100661360A5047918797 @default.
• W2100661360 hasAuthorship W2100661360A5049161137 @default.
• W2100661360 hasAuthorship W2100661360A5051351236 @default.
• W2100661360 hasAuthorship W2100661360A5052023186 @default.
• W2100661360 hasAuthorship W2100661360A5056455853 @default.
• W2100661360 hasAuthorship W2100661360A5071176191 @default.
• W2100661360 hasAuthorship W2100661360A5071199136 @default.
• W2100661360 hasAuthorship W2100661360A5072563567 @default.
• W2100661360 hasAuthorship W2100661360A5074489260 @default.
• W2100661360 hasAuthorship W2100661360A5076489880 @default.
• W2100661360 hasAuthorship W2100661360A5085797478 @default.

• next